Videos

Findings from the NPCA – performance indicators in radiotherapy

Presented by Dr Alison Tree, Consultant Clinical Oncologist, The Royal Marsden NHS Foundation Trust, and NPCA Clinical Lead for Oncology, for the NPCA QI event 2024.

Prostate Radiotherapy Masterclass – Clatterbridge/ Royal Marsden (Part 1)

Presented by Dr Julia Murray, Consultant Clinical Oncologist, The Royal Marsden NHS Foundation Trust, for the NPCA QI event 2024.

Prostate Radiotherapy Masterclass – Clatterbridge/ Royal Marsden (Part 2)

Presented by Professor Isabel Syndikus, Consultant in Clinical Oncology, The Clatterbridge Cancer Centre NHS Foundation Trust, for the NPCA QI event 2024.

Capacity for assessing/optimising patients prior to treatment – Oncogeriatric perspective

Presented by Dr Tania Kalsi, Consultant in geriatric and general internal medicine, Guy’s and St Thomas’ NHS for the NPCA 2024 QI event.

Capacity for delivery – who can prescribe systemic therapy? Example of excellence – Dudley

Presented by Georgia Malesi, Principal Pharmacist for Cancer Services, The Dudley Group NHS Foundation Trust, for the NPCA 2024 QI event.

NPCA Quality Improvement Workshop 2024: Panel discussion

Patient view and reflections : Terence Bytheway

Presented by Terence Bytheway, NPCA Patient and Public Involvement Forum representative at the NPCA Quality Improvement event 2024.

Patient view & reflections: Steve Allen

What are the future priorities for the NPCA? Panel discussion

Introducing the National Cancer Audit Collaborating Centre and the future direction of the NPCA

Determinants of variation in the diagnosis & treatment of patients with metastatic disease

Evaluating performance in prostate cancer – NPCA surgical & radiotherapy outcome reporting programme

10 years of the NPCA

Applying learnings from the pandemic to the future direction of PCa care

Campaign to find the ‘missing men’: update from Prostate Cancer UK

Update on NHS England’s Covid Action Plan

Update on the impact of the Covid-19 pandemic on the diagnosis & treatment of prostate cancer

10 years of the NPCA and future direction

Quality Improvement workshop 03.02.23

Reducing variation in the treatment of men with high risk/locally advanced prostate cancer

NPCA Quality Improvement Workshop, 16.12.21

Impact of the Covid-19 pandemic: findings from the National Prostate Cancer Audit

Julie Nossiter, NPCA Audit Lead, RCSEng/ Assistant professor, LSHTM

Update on NHS England’s Data and Action Plan

Peter Johnson, National Clinical Director for Cancer, NHS England/ Professor of Medical Oncology, University Hospital, Southampton

Panel discussion highlights: How has the COVID-19 pandemic impacted prostate cancer services?

Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England

Matt Parry, NPCA Clinical Fellow/ Urology Registrar

Optimising the management of patients with high risk/locally advanced disease – improving the outcomes of older men

Danielle Harari, Geriatric-oncology Consultant and Clinical Lead, Geriatric Oncology liaison Development Team, Guy’s and St. Thomas’

Panel discussion highlights: Determinants of variation in the treatment of high risk/locally advanced prostate cancer

How do we reduce variation in access to treatment for all men? The experience of black and ethnic minority groups

Jonathan Makanjuola, Consultant Urological Surgeon, King's College Hospital

NPCA Interview with Stephen Fry

How can the NPCA best support quality improvement?

What are the priorities for improving the quality of care for prostate cancer patients?

Reducing treatment-related toxicity after radical prostate cancer treatment

A national quality improvement workshop for clinicians